Edwards Lifesciences announced the appointment of Theodora “Doretta” Mistras as Corporate Vice President and Chief Financial Officer, effective at the end of May. Mistras will succeed Scott Ullem, who previously announced plans to step down as CFO in October.
Mistras joins Edwards from Viatris, where she has served as Chief Financial Officer since March 2024, overseeing the company’s global finance organization, financial planning, reporting, and operational finance activities.
Prior to Viatris, Mistras was a Managing Director in Citigroup Global Markets’ healthcare investment banking group. Earlier in her career, she held senior leadership roles in healthcare investment banking at Goldman Sachs.
Edwards said Mistras brings decades of experience in healthcare finance, corporate strategy, investor relations, and board advisory.
She holds a bachelor’s degree in international studies from the University of Pennsylvania and a bachelor’s degree in economics from the Wharton School.
Ullem has served as Chief Financial Officer of Edwards Lifesciences since 2014.
Edwards Lifesciences is a global structural heart innovation company focused on medical technologies and therapies designed to improve patient outcomes.
KEY QUOTES:
“We are very pleased to welcome Doretta to Edwards as our next CFO.”
“Doretta’s broad experience will be instrumental as we execute our differentiated strategy.”
“We look forward to her leadership as we continue to invest in innovation, and also deliver distinguished and durable financial results and long-term value to patients, customers, shareholders and the broader healthcare ecosystem.”
Bernard Zovighian, CEO, Edwards Lifesciences
“We would like to once again thank Scott for his outstanding leadership, partnership and impact.”
“His commitment to a thoughtful transition and his continued support as a strategic advisor in the months ahead reflects the discipline and continuity that have long defined Edwards’ approach to leadership.”
“We are grateful for Scott’s numerous contributions over the years that have helped to strengthen our company both strategically and financially.”
Bernard Zovighian, CEO, Edwards Lifesciences
